Press Releases

Asthma Drugs Market Size Set to Surpass US$ 34.28 Billion by 2030

Share This Article

The global asthma drugs market size is expected to surpass US$ 34.28 billion by 2030 and is anticipated to grow with a healthy growth rate of 5.2% from 2022 to 2030.

Asthma is considered to be one of the world’s most common diseases affecting the population, and is also a life-threatening condition affecting patients’ regular breathing. Asthma is a persistent condition that stretches and narrows the air passages of the lungs, causing constant assaults of breathlessness, bronchospasm and reversible obstruction of airflow. Air toxicity, cigarette smoke, environmental irritants, indoor and outdoor allergens are major causes of asthma. In an increasing number of urban and rural areas, there is a substantial rise in asthma cases due to an increase in air quality.

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1225

There is a large rise in the number of cigarettes, which contributes to asthma symptoms. In addition, the rise in industrialization has also contributed to an increase in the number of cases of asthma, which, over the forecast era, would drive the demand for global asthma drugs. The giants of pharmaceutical companies are steadily investing in their R&D activities to develop better medicines for asthma, which are also expected to fuel the target market. In addition, current advances in the healthcare sector are providing groundbreaking therapies that are expected to further fuel the growth of the target market over the forecast timeframe.

Growth Factors:

Increasing prevalence of asthma across the globe is major factor driving growth of the global asthma drugs market. Asthma is deliberated as the common chronic diseases. Increasing need for better and improved health is creating huge demand for the asthma medications which will in turn fuel growth of the global market in the near future. As per the data published by Pharmaceutical Services Negotiating Committee (PSNC), in 2016, more than 5.5 million people in the UK received asthma treatment out of which 4.3 million were adults and 1.1 million asthma patients were children.

In order to cater the growing demand for asthma drugs, key market players are repeatedly launching advanced and innovative products at minimum costs which is will support and boost growth of the asthma industry in the next 10 years. For instance, in year 2019, AstraZeneca company’s asthma drug Fasenra has been approved by the Food and Drug Administration which is a pre filled and auto injector. Additionally, in the same year GlaxoSmithKline plc.’s Nucala has been approved by the Food and Drug Administration in order to treat severe eosinophilic asthma for the children in the six to eleven year of age group. This is the only biologic approved for the younger age group. Additionally, rising R&D activities, technological advancements, government support for creating health awareness are among major factors that will augment target industry growth during the forecast time-frame.

Market Scope of Asthma Drugs Market 

Report Highlights Details
Market Size USD 34.65 Billion by 2030
Growth Rate CAGR of 5.2% From 2022 to 2030
Base Year 2021
Historic Data 2017 to 2021
Forecast Period 2022 to 2030
Segments Covered Medication, Mode of Administration, Source, Organization Type, Application
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

COVID-19 Impact:

The industrial report mentions the influence of the ongoing COVID-19 pandemic. The outbreak has caused disturbances in several industries and has hammered the logistics, resulting in delayed deliveries and cancellation of product demand. The asthma drugs report proficiently explains the resulting factors and concerns of manufacturers. Researchers have also well-explained how the producers and providers will tackle the ongoing epidemic and the key strategies to be adopted post-pandemic for turning their businesses back to normal.

Report Highlights:

  • Among the asthma drugs medications type segment long-term control medications segment is dominated the overall market. The growth is attributed to growing need for the long-term control medications in order to treat chronic diseases that are considered as asthma. Further the quick relief medications segment is projected register significant share in the global industry owing its increased consumer base across the globe.
  • Novartis accounted for a significant share of the global asthma drugs market.
  • Tablets and capsules segment is expected to hold the prime revenue share by mode of administration.
  • Long-term control medications segment is expected to hold the prime revenue share by medication type.

Regional Analysis:
The research report deals with the industry prospects of asthma drugs products around regions including Europe, North America, Latin America, Asia-Pacific, and Middle East and Africa. North America will dominate the global industry due to huge investments in healthcare sector and growing research and development activities in the countries is predictable create tremendous demand for the asthma drugs, in the countries of the North America. Presence of leading players in the region along with strategies that are implemented by the major players in the countries of North America is expected to witness substantial growth in the target industry in the near future.

Asia Pacific is likely to list the noteworthy CAGR, on account of increased initiatives by the government in order to creates awareness regarding health in emerging economies. Also, most of the key players operating in the industry are investing heavily in order to get the competitive edge in the asthma drugs market in Asia Pacific. Addition to this growth of the European countries is attributed to the growing focus on research and development activities and increasing old age population in the France, Russia, and U.K. of the region. Latin America asthma drugs market is expected to grow at moderate CAGR in the near future. Also, Middle East and Africa region is expected to create lucrative growth opportunities in the target industry.

Key Players:

The asthma drugs market is consolidated with a major number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research.

Some of the prominent players in the asthma drugs market include:

  • GlaxoSmithKline
  • Pfizer
  • Vectura Group
  • Boehringer Ingelheim
  • Roche
  • Novartis
  • Merck
  • AstraZeneca
  • Teva Pharmaceutical

Market Segmentation

By Medication

  • Quick Relief Medications
  • Long-term Control Medications
  • Others

By Mode of Administration

  • Tablets and Capsules
  • Liquids
  • Inhalers
  • Injections
  • Sprays and Powders

By Source

  • Environmental
  • Generic

By Organization Type

  • Public
  • Private

By Application

  • Pediatric
  • Adults
  • Adolescent

Regional Segmentation

  • North America (U.S. and Canada)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Asthma Drugs Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Asthma Drugs Market

5.1. Covid-19: Asthma Drugs Industry Impact
5.2. Asthma Drugs Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Asthma Drugs Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Asthma Drugs Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Asthma Drugs Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing prevalence of asthma, along with increase in ageing population
6.1.1.2. Increase in pipeline products growth in initiatives implemented by the government and non-government associations for rise in health awareness
6.1.2. Market Restraints
6.1.2.1. Stringent government regulatory requirement for the approval of asthma drugs
6.1.3. Market Opportunities
6.1.3.1. Major companies are focusing on broadening their product portfolio

Chapter 7. Global Asthma Drugs Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Asthma Drugs Market Revenue by Market Players (2017 – 2020)
7.1.1.2. Asthma Drugs Market Revenue Market Share by Market Players (2017 – 2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Process Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Asthma Drugs Market, By Medication Type

8.1. Asthma Drugs Market, by Medication Type, 2017-2030
8.1.1. Quick Relief Medications
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Long-term Control Medications
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Asthma Drugs Market, By Mode of Administration

9.1. Asthma Drugs Market, by Mode of Administration, 2017-2030
9.1.1. Tablets and Capsules
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Liquids
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Inhalers
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Injections
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Sprays and Powders
9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Asthma Drugs Market, By Source

10.1. Asthma Drugs Market, by Source, 2017-2030
10.1.1. Environmental
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Generic
10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Asthma Drugs Market, By Organization Type

11.1. Asthma Drugs Market, by Application, 2017-2030
11.1.1. Public
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Private
11.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Asthma Drugs Market, By Application

12.1. Asthma Drugs Market, by Application, 2017-2030
12.1.1. Pediatric
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Adults
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Adolescent
12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Asthma Drugs Market, Regional Estimates and Trend Forecast

13.1. North America
13.1.1. Market Revenue Forecast by Medication Type (2017-2030)
13.1.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.1.3. Market Revenue Forecast by Source (2017-2030)
13.1.4. Market Revenue Forecast by Organization Type (2017-2030)
13.1.5. Market Revenue Forecast by Application (2017-2030)
13.1.6. U.S
13.1.6.1. Market Revenue Forecast (2017-2030)
13.1.7. Canada
13.1.7.1. Market Revenue Forecast (2017-2030)
13.2. Europe
13.2.1. Market Revenue Forecast by Medication Type (2017-2030)
13.2.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.2.3. Market Revenue Forecast by Source (2017-2030)
13.2.4. Market Revenue Forecast by Organization Type (2017-2030)
13.2.5. Market Revenue Forecast by Application (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue Forecast (2017-2030)
13.2.7. Germany
13.2.7.1. Market Revenue Forecast (2017-2030)
13.2.8. France
13.2.8.1. Market Revenue Forecast (2017-2030)
13.2.9. Rest of EU
13.2.9.1. Market Revenue Forecast (2017-2030)
13.3. Asia Pacific (APAC)
13.3.1. Market Revenue Forecast by Medication Type (2017-2030)
13.3.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.3.3. Market Revenue Forecast by Source (2017-2030)
13.3.4. Market Revenue Forecast by Organization Type (2017-2030)
13.3.5. Market Revenue Forecast by Application (2017-2030)
13.3.6. China
13.3.6.1. Market Revenue Forecast (2017-2030)
13.3.7. India
13.3.7.1. Market Revenue Forecast (2017-2030)
13.3.8. Japan
13.3.8.1. Market Revenue Forecast (2017-2030)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue Forecast (2017-2030)
13.4. LATAM
13.4.1. Market Revenue Forecast by Medication Type (2017-2030)
13.4.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.4.3. Market Revenue Forecast by Source (2017-2030)
13.4.4. Market Revenue Forecast by Organization Type (2017-2030)
13.4.5. Market Revenue Forecast by Application (2017-2030)
13.4.6. Brazil
13.4.6.1. Market Revenue Forecast (2017-2030)
13.4.7. Rest of LATAM
13.4.7.1. Market Revenue Forecast (2017-2030)
13.5. Middle East and Africa (MEA)
13.5.1. Market Revenue Forecast by Medication Type (2017-2030)
13.5.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.5.3. Market Revenue Forecast by Source (2017-2030)
13.5.4. Market Revenue Forecast by Organization Type (2017-2030)
13.5.5. Market Revenue Forecast by Application (2017-2030)
13.5.6. GCC
13.5.6.1. Market Revenue Forecast (2017-2030)
13.5.7. North Africa
13.5.7.1. Market Revenue Forecast (2017-2030)
13.5.8. South Africa
13.5.8.1. Market Revenue Forecast (2017-2030)
13.5.9. Rest of MEA
13.5.9.1. Market Revenue Forecast (2017-2030)

Chapter 14. Company Profiles

14.1. Pfizer
14.1.1. Company Overview, Business Information, Regional Presence
14.1.2. Product Portfolio Analysis
14.1.2.1. Product Details, Specification, Product Type
14.1.3. Revenue, Price, and Gross Margin (2017-2020)
14.1.4. Recent Developments and Strategies
14.2. GlaxoSmithKline
14.2.1. Company Overview, Business Information, Regional Presence
14.2.2. Product Portfolio Analysis
14.2.2.1. Product Details, Specification, Product Type
14.2.3. Revenue, Price, and Gross Margin (2017-2020)
14.2.4. Recent Developments and Strategies
14.3. Novartis
14.3.1. Company Overview, Business Information, Regional Presence
14.3.2. Product Portfolio Analysis
14.3.2.1. Product Details, Specification, Product Type
14.3.3. Revenue, Price, and Gross Margin (2017-2020)
14.3.4. Recent Developments and Strategies
14.4. Merck
14.4.1. Company Overview, Business Information, Regional Presence
14.4.2. Product Portfolio Analysis
14.4.2.1. Product Details, Specification, Product Type
14.4.3. Revenue, Price, and Gross Margin (2017-2020)
14.4.4. Recent Developments and Strategies
14.5. Boehringer Ingelheim
14.5.1. Company Overview, Business Information, Regional Presence
14.5.2. Product Portfolio Analysis
14.5.2.1. Product Details, Specification, Product Type
14.5.3. Revenue, Price, and Gross Margin (2017-2020)
14.5.4. Recent Developments and Strategies
14.6. AstraZeneca
14.6.1. Company Overview, Business Information, Regional Presence
14.6.2. Product Portfolio Analysis
14.6.2.1. Product Details, Specification, Product Type
14.6.3. Revenue, Price, and Gross Margin (2017-2020)
14.6.4. Recent Developments and Strategies
14.7. Roche
14.7.1. Company Overview, Business Information, Regional Presence
14.7.2. Product Portfolio Analysis
14.7.2.1. Product Details, Specification, Product Type
14.7.3. Revenue, Price, and Gross Margin (2017-2020)
14.7.4. Recent Developments and Strategies
14.8. Teva Pharmaceutical
14.8.1. Company Overview, Business Information, Regional Presence
14.8.2. Product Portfolio Analysis
14.8.2.1. Product Details, Specification, Product Type
14.8.3. Revenue, Price, and Gross Margin (2017-2020)
14.8.4. Recent Developments and Strategies
14.9. Vectura Group
14.9.1. Company Overview, Business Information, Regional Presence
14.9.2. Product Portfolio Analysis
14.9.2.1. Product Details, Specification, Product Type
14.9.3. Revenue, Price, and Gross Margin (2017-2020)
14.9.4. Recent Developments and Strategies

Chapter 15. Appendix

15.1. About Us
15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1225

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Related Articles

Back to top button